November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Iris-claw phakic IOL found to be safe for treating hyperopia
October 1st 2003Stanford, CA-The phase III trial of the iris-claw phakic IOL (Artisan, Ophtec) for the treatment of hyperopia is now 2 years post- launch, and the short- and long-term results from the interim analyses are very encouraging, said Edward E. Manche, MD.
Read More
Vision outcomes create optimistic expectation for spectacle independence
October 1st 2003Editor's Note: The CrystaLens was recommended for approval by the FDA's Ophthalmic Devices Advisory Panel in late May. The lens may be commercially available later this year or early 2004. Dr. Doane's presentation was given at the annual meeting of the American Society of Cataract and Refractive Surgery prior to the recommendation.
Read More
Oval-flap technique affords increased LASIK safety
September 1st 2003San Francisco-An investigational oval suction ring for the Carriazo-Pendular microkeratome (Schwind) allows for optimal suction even in astigmatic eyes and maximizes the ablatable area of the stromal bed, according to its inventor.
Read More
Fluoroquinolone more effective against gram-positive bacteria
August 1st 2003Fort Lauderdale, FL-Gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) shows clearly improved activity against commonly encountered gram-positive ocular bacteria in vitro compared with older fluoroquinolones. This fourth-generation fluoroquinolone received FDA approval in March (see related article, Ophthalmology Times, May 1 issue, Page 1).
Read More
PDT safe choice for eyes with predominantly classic CNV
August 1st 2003Fort Lauderdale, FL-In eyes with predominantly classic subfoveal choroidal neovascularization (CNV) treated with photo- dynamic therapy (PDT) using verteporfin (Visudyne, Novartis Ophthalmics), vision remained stable and the need for additional treatment decreased dramatically over time, reported Peter K. Kaiser, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Moxifloxacin hastens resolution of bacterial conjunctivitis
August 1st 2003Fort Lauderdale, FL-A 4-day course of moxifloxacin ophthalmic solution 0.5% (Vigamox, Alcon) is a safe and effective treatment for bacterial conjunctivitis in adults and children as young as 1 month old, according to results from a phase III FDA study, reported Harold R. Katz, MD, who spoke on behalf of the Moxifloxacin Conjunctivitis Study Group at the annual meeting of the Association for Research in Vision and Ophthalmology. The fourth-generation fluoroquinolone received FDA approval in April for the treatment of bacterial conjunctivitis (see related article, Ophthalmology Times, June 1, 2003 issue, Page 1).
Read More
Multiple-dose regimen safe for neovascular AMD
August 1st 2003Fort Lauderdale, FL-In a phase I, multicenter, randomized trial, the anti-VEGF antibody fragment rhuFab V2 was shown to be safe and well-tolerated in eyes with neovascular age-related macular degeneration (AMD), according to Philip J. Rosenfeld, MD, PhD.
Read More
eDiary collected patient results for approved drug
August 1st 2003Pittsburgh-When the FDA recently approved ketorolac tromethamine ophthalmic solution (Acular LS 0.4%, Allergan), history was made on several fronts. Not only was it a banner day for Allergan, whose solution won approval, but it represented the first time an electronic patient diary was used to collect and tabulate primary efficacy data for a phase III pivotal trial.
Read More
LASIK a viable choice in select group of children
July 15th 2003San Francisco-Pediatric LASIK is an investigational procedure, but it can be a feasible and safe modality for young patients with anisometropic amblyopia who truly have no other option for improving best-corrected vision, said Jonathan M. Davidorf, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Read More
Brimonidine battle begins with B&L launch
July 15th 2003Rochester, NY-Now that Bausch &Lomb has won its battle to release its generic version of brimonidine tartrate ophthalmic solution 0.2% (Alphagan, Allergan), the ophthalmic industry is waiting to see whether physicians will choose the generic version of the old standard or brimonidine tartrate 0.15% (Alphagan P, Allergan).
Read More
Transitions instructors expanding territories
July 15th 2003Pinellas Park, FL-A 34-member team from Transitions Optical Solutions is working with eye-care practices across the United States and Canada to promote the company's business-building strategies, product information, and training resources.
Read More
Blue-blocking lens performs like standard UV-absorbing model
July 1st 2003San Francisco-The AcrySof Natural IOL (Model SB30AL, Alcon), containing a covalently bonded, blue light-filtering chromophore (ImprUV), more closely mimics the light transmission spectrum of the precataractous adult human crystalline lens compared with standard UV-absorbing IOLs without any adverse effects on vision, said Paul H. Ernest, MD, at the American Society of Cata-ract and Refractive Surgery an-nual meeting.
Read More
Goldberg passes baton to new Wilmer director
July 1st 2003Baltimore-Morton Goldberg, MD, will enter a new phase of his career this month when he will step down as director of the Wilmer Eye Institute, Johns Hopkins University School of Medicine. Effective July 1, Peter J. McDonnell III, MD, chairman of the ophthalmology department at the University of California-Irvine, will take the helm as the institute's new director (See Page 10).
Read More
Implantable telescope enters pivotal trial for AMD patients
June 1st 2003Saratoga, CA-A pivotal trial has begun with the implantable miniature telescope (IMT) (VisionCare Ophthalmic Technologies Inc., Saratoga, CA), a low vision IOL for patients with age-related macular degeneration (AMD), following a successful phase I trial. In that trial, most patients gained three or more lines of near or distance visual acuity and improved their ability to perform daily activities.
Read More